Charles River Laboratories International (NYSE:CRL – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 10.900-11.400 for the period, compared to the consensus earnings per share estimate of 10.790. The company issued revenue guidance of $4.2 billion-$4.3 billion, compared to the […]
By Denny Jacob Charles River Laboratories International shares were up 8.7% at $239.28 following its guidance for 2024. The stock, down about 5% over the.
State of New Jersey Common Pension Fund D decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 2.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 28,786 shares of the medical research company’s stock after selling 806 shares during the […]
Anchor Capital Advisors LLC trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 4.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 119,274 shares of the medical research company’s stock after selling 5,308 shares […]
Bryn Mawr Capital Management LLC cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 3.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,809 shares of the medical research company’s stock after […]